fbpx Skip to main content
 

Search

Janssen Search

Search results

474 SEARCH RESULTS FOR

innovation

Not finding what you're looking for? Visit Janssen in your country.
PAGE 31 OF 48

Pages

SANJAYA SINGH, Ph.D. GLOBAL HEAD JANSSEN BIOTHERAPEUTICS (JBIO) Sanjaya Singh, Ph.D., is the Global Head of Janssen BioTherapeutics, the biotherapeutics engine of Janssen Research & Development. He is responsible for leading an organization of more ...

ELIZABETH FORMINARD General Counsel Pharmaceuticals Liz Forminard is General Counsel, Pharmaceuticals and is responsible for legal matters relating to the Pharmaceuticals Group globally. In addition, the Legal group providing support to Johnson & ...

RICHARD (DICK) INSEL, M.D. GLOBAL HEAD HEALTHY BABY INITIATIVE WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Healthy Baby Initiative, World Without Disease Accelerator (WWDA), Dick is leading a strategy focused on changing the trajectory of health for ...

Discovery & Development Our portfolio is fueled by our world-class discovery and development teams and external collaborators. We continue to work to deliver innovative solutions that contribute to the global fight against infectious diseases and ...

Welcome to the Janssen Immunology ACG 2020 Newsroom! Please see below for the latest meeting news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for Inflammatory Bowel ...

EMMANUELLE QUILÈS WORLDWIDE VICE PRESIDENT CARDIOVASCULAR, METABOLISM AND PULMONARY HYPERTENSION JANSSEN GLOBAL COMMERCIAL STRATEGY ORGANIZATION (GCSO) Emmanuelle Quilès is Worldwide Vice President, Cardiovascular, Metabolism and Pulmonary Hypertension. ...

CANDICE LONG WORLDWIDE VICE PRESIDENT IMMUNOLOGY Candice Long is the Worldwide Vice President for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology Research & Development ...

Products and Packaging We’re committed to delivering the highest quality products for patients, doctors and customers, while also working to reduce our environmental footprint. Our approach includes integrating sustainable design solutions into our ...

Aug 27, 2024 Belgium Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI [1], [2], [3], [4] ​ Amivantamab ...

Building a Compassionate Culture that Supports Caregivers in the Workplace and Beyond At the Janssen Pharmaceutical Companies of Johnson & Johnson, we recognize all those who assume the responsibility of caring for a loved one with a serious illness ...

474 SEARCH RESULTS FOR

innovation

Not finding what you're looking for? Visit Janssen in your country.
PAGE 31 OF 48

Pages